- Record: found
- Abstract: not found
- Article: not found
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
Paresh Dandona ,
Chantal Mathieu ,
Moshe Phillip ,
Lars Hansen ,
Steven C Griffen ,
Diethelm Tschöpe ,
Fredrik Thorén ,
John Xu ,
Anna Maria Langkilde ,
Joseph Proietto ,
Stephen Stranks ,
Roger Chen ,
David O'Neal ,
Alexia Pape ,
Mark Forbes ,
Claire Morbey ,
Anton Luger ,
Ursula Hanusch ,
Christoph Schnack ,
Evelyn Fliesser-Goerzer ,
Bertram Hoelzl ,
Christoph Ebenbichler ,
Rudolf Prager ,
Luc Van Gaal ,
Chris Vercammen ,
Andre Scheen ,
Chantal Mathieu ,
Francis Duyck ,
Frank Nobels ,
Johannes Ruige ,
Naresh Aggarwal ,
Vincent Woo ,
Bruno St-Pierre ,
Richard Dumas ,
Irene Hramiak ,
Thomas Elliott ,
Troels Krarup Hansen ,
Jan Erik Henriksen ,
Jeppe Gram ,
Aina Lihn ,
Jens Bruun ,
Juha Saltevo ,
Jyrki Taurio ,
Jorma Strand ,
Timo Valle ,
Sakari Nieminen ,
Kirsi Pietilainen ,
Bruno Guerci ,
Samy Hadjadj ,
Bertrand Cariou ,
Bruno Verges ,
Sophie Borot ,
Alfred Penfornis ,
Thomas Schaum ,
Diethelm Tschoepe ,
Cornelia Marck ,
Thomas Horacek ,
Ludger Rose ,
Gerhard Klausmann ,
Joerg Luedemann ,
Steffi Appelt ,
Ulrich Aigner ,
Rolf Goebel ,
Thomas Behnke ,
Anette-Gabriele Ziegler ,
Eva Peterfai ,
Zsuzsanna Kerenyi ,
Tamas Oroszlan ,
Gyula G. Kiss ,
Laszlo Konyves ,
Gyorgyi Piros ,
Moshe Phillip ,
Ofri Mosenzon ,
Naim Shehadeh ,
Faiad Adawi ,
Julio Wainstein ,
Francesco Dotta ,
Piermarco Piatti ,
Stefano Genovese ,
Agostino Consoli ,
Paolo Di Bartolo ,
Edoardo Mannucci ,
Carla Giordano ,
Annunziata Lapolla ,
Carlos Aguilar ,
Alberto Esteban ,
Bazzoni Ruiz ,
Guillermo Mondragon Ramirez ,
Emilia Pelayo Orozco ,
Carlos Alejandro ,
Stobschinski de Alba ,
Carlos Medina Pech ,
Jose Garza Ruiz ,
Leobardo Sauque Reyna ,
Guillermo Llamas Esperon ,
Luis Alejandro Nevarez Ruiz ,
Maricela Vidrio Velazquez ,
Fernando Flores Lozano ,
Jose Gerardo Gonzalez Gonzalez ,
Pedro Alberto Garcia-Hernandez ,
Roberto Araujo-Silva ,
Efrain Villeda - Espinosa ,
Cristina Mistodie ,
Daniela Popescu ,
Ciprian Constantin ,
Alina Nicolau ,
Bogdan Popa ,
Romulus Timar ,
Cristian Serafinceanu ,
Ella Pintilei ,
Alfonso Soto ,
Margarita Gimenez ,
Juan Francisco Merino-Torres ,
Cristobal Morales ,
Pedro Mezquita ,
Johan Jendle ,
Bengt-Olov Tengmark ,
Jan Eriksson ,
Magnus Londahl ,
Bjorn Eliasson ,
Anthony Gunstone ,
Simon Heller ,
Ken Darzy ,
Peter Mansell ,
Melanie Davies ,
Rory Reed ,
Duncan Browne ,
Hamish Courtney ,
Wayne Turner ,
Mark Blagden ,
Rory McCrimmon ,
Richard Bergenstal ,
Wendy Lane ,
Kathryn Lucas ,
Alexander White ,
Shichun Bao ,
Judith White ,
Curtis Jantzi ,
Neda Rasouli ,
William Ervin ,
Lorena Lewy-Alterbaum ,
Yehuda Handelsman ,
Bresta Miranda-Palma ,
Alan Cleland ,
Raymond Fink ,
Helena Rodbard ,
Samer Nakhle ,
Craig Greenberg ,
Alan Schorr ,
Harold Bays ,
Debra Simmons ,
Eric Klein ,
Laurie Kane ,
Norman Fishman ,
Eli Ipp ,
Satish Garg ,
Anuj Bhargava ,
Michelle Zaniewski Singh ,
Julio Rosenstock ,
James Thrasher ,
Mark Warren ,
Laura Young ,
Vanita Aroda ,
Jeremy Pettus ,
David Liljenquist ,
Robert Busch ,
Paresh Dandona ,
Jonathan Wise ,
David Kayne ,
William Biggs
November 2017
November 2017
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment
of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as
an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes.